Prenetics Global Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Prenetics Global
Pharmaceutical Preparations, SIC 2834
Prenetics is a consumer health and longevity enterprise that develops science-backed nutritional products and genetic testing solutions. The organization operates through two primary business units: IM8, its core consumer health brand, and CircleDNA, its prevention brand. IM8 provides daily nutritional and cellular health supplements, including all-in-one daily formulations, longevity supplements, and bundled regimens. CircleDNA delivers personalized genetic testing kits using next-generation sequencing across health, wellness, and disease risk categories. The company sells its offerings directly to retail consumers worldwide through proprietary e-commerce platforms and subscription plans.
Incorporated in the Cayman Islands, Prenetics maintains its corporate registered office in Quarry Bay, Hong Kong. The business serves a global customer base across more than 30 countries, with primary international distribution markets that include the United States, Canada, the United Kingdom, Australia, and Singapore. Its dietary supplements are manufactured in third-party facilities located in the United States and shipped to consumers globally.
Summary of the business section of Prenetics Global's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Prenetics Global Ltd
- Founded
- 2014
- Headquarters
- Quarry Bay, K3
- Address
- 7/F, K11 Atelier, 728 King'S Road 000000
- Phone
- (852) 2210-7188
- Website
- prenetics.com
- Employees
- 98, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- Deloitte Touche Tohmatsu, Hong Kong
Stock & identifiers
- Ticker
- PRE
- Other tickers
- PRENW
- Exchange
- Nasdaq
- Shares outstanding
- 17M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-15 reverse, May 1, 2024; 1-for-15 reverse, Nov 14, 2023
- SEC CIK
- 1876431
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Danny Sheng Wu Yeung | Chief Executive Officer, Director | 1,682,207 |
| Thuan Yen Tat | VP, Finance of IM8 (US) LLC | – |
| Brian J. Rosin | CFO of IM8 (US) LLC | 23,100 |
| Hoi Chun Lo | Chief Financial Officer | 566,013 |
| Hudson Blake Leogrande | Director | 6,001 |
| Caroline S. Levy | Director | – |
| Yin Pan Cheng | Director | 59,051 |
| David Vanderveen | Director | 46,897 |
| Darshan Ravindra Shah | Director | 4,506 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 98 full-time employees and 30 service contractors across eight countries, including Hong Kong, Malaysia and the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 17, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 9, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |